A recombinant pseudorabies virus, its construction method and application
By constructing a recombinant virus with the US2 gene deleted from pseudorabies virus using CRISPR/Cas9 gene editing technology, the immunosuppression problem of pseudorabies virus variants was solved, significantly improving the host's antiviral immune response, and making it suitable for the development of novel gene-deleted vaccines.
Patent Information
- Application Number
- CN202311311456.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-11
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-10-11
AI Technical Summary
The existing classic Bartha K61 attenuated live vaccine has a weak neutralizing ability against pseudorabies virus variants, resulting in poor immune protection. Furthermore, pseudorabies virus suppresses the host's antiviral immune response through the US2 protein, making it difficult to effectively control viral infection.
Recombinant viruses with the US2 gene missing from pseudorabies virus were constructed using CRISPR/Cas9 gene editing technology. This significantly reduced US2 protein expression, increased the expression of type I IFNb and downstream ISGs in host cells, and reduced immunosuppression.
Recombinant pseudorabies virus significantly increases the expression of type I IFNb and downstream ISGs after infecting host cells, while reducing viral replication without significant difference, demonstrating a significant immune-enhancing effect and making it suitable for the development of novel gene-deleted vaccines.
Smart Images

Figure CN117286120B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, and in particular to a recombinant pseudorabies virus, its construction method, and its application. Background Technology
[0002] Pseudorabies is an acute infectious disease caused by pseudorabies virus (PRV), affecting various livestock and mammals, and causing significant economic losses to my country's livestock industry. Pigs are the natural host and reservoir of this virus. During the breeding process, PRV infection can cause abortion and stillbirth in pregnant sows, infertility in boars, neurological disorders and rapid death in piglets, and respiratory diseases and slow growth in finishing pigs. In 2011, the emergence of a variant strain caused adult pigs to exhibit severe symptoms similar to those in piglets, adding new challenges to the prevention and control of the disease. The most effective way to prevent porcine pseudorabies is vaccination, but the antibodies produced by the classic Bartha K61 attenuated live vaccine have weak neutralizing ability against currently circulating strains and can no longer provide highly effective protection. Given the current prevalence of porcine pseudorabies, it is necessary to modify the PRV variant strain and develop a new gene-deleted vaccine with stronger immunogenicity and better safety to effectively prevent and control porcine pseudorabies.
[0003] The host's innate immune system is the first line of defense against infection. To adapt to host cells, herpesviruses such as pseudorabies virus have evolved various strategies to antagonize the host's antiviral immune response. These immune escape strategies are crucial for establishing persistent infection within the host. For example, studies have shown that when pseudorabies virus infects cells, its encoded mesenchymal protein US3 significantly inhibits interferon (IFN)-induced activation of STAT1 and the expression of its downstream ISGs, reducing the production of antiviral proteins. This indicates that pseudorabies virus can suppress the host's IFN-mediated antiviral immune response. Furthermore, studies have found that pseudorabies virus phosphorylated kinase UL13 downregulates the cGAS-STING signaling pathway, inhibiting type I interferon production. In summary, pseudorabies virus can suppress the host's antiviral innate immune response through various viral proteins. However, to date, there are no reports on constructing a pseudorabies variant with the US2 gene deletion. Summary of the Invention
[0004] The purpose of this invention is to provide a recombinant pseudorabies virus, its construction method, and its application, in order to solve the problems existing in the prior art. After the recombinant pseudorabies virus infects host cells, it induces a significant increase in the expression of type I IFNb and downstream ISG genes, while the replication of the virus itself is not significantly different. It can significantly reduce the immunosuppression caused by pseudorabies virus and has important potential application value.
[0005] To achieve the above objectives, the present invention provides the following solution:
[0006] This invention provides a recombinant pseudorabies virus, which is obtained by deleting the US2 gene from pseudorabies virus.
[0007] The present invention also provides a method for constructing the recombinant pseudorabies virus, including the steps of inhibiting the expression of the US2 gene in the pseudorabies virus or reducing the content of the US2 protein in the pseudorabies virus.
[0008] Furthermore, the inhibition of US2 gene expression in pseudorabies virus is achieved through CRISPR / Cas9 gene editing.
[0009] Further, the steps for inhibiting the expression of the US2 gene in pseudorabies virus are as follows: a gRNA for specifically targeting the target gene is designed based on the US2 gene sequence of pseudorabies virus, and the gRNA is then ligated to a linearized vector. After transformation, extraction, and transfection, the wild-type strain is infected to obtain the recombinant pseudorabies virus.
[0010] Furthermore, the target sequence of the gRNA on the target gene conforms to the 5'-N sequence. 20 -NGG-3' or 5'-CCN-N 20 -3' sequence site.
[0011] Furthermore, the nucleotide sequence of the target sequence is shown in SEQ ID No. 2 and SEQ ID No. 3; the sequence of the gRNA is shown in SEQ ID No. 4 and SEQ ID No. 5.
[0012] The present invention also provides the application of an agent that inhibits the expression of the US2 gene or reduces the content of the US2 protein in pseudorabies virus in the preparation of pseudorabies virus vaccine.
[0013] Furthermore, the US2 protein is a protein of the following type (1) or (2):
[0014] (1) Its amino acid sequence is shown in SEQ ID No. 1;
[0015] (2) It has more than 98% identity with the amino acid sequence shown in SEQ ID No.1 and is a homologous protein derived from pseudorabies virus.
[0016] Furthermore, the identity refers to the identity of amino acid sequences. The identity of amino acid sequences can be determined using homology search sites on the Internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, by using blastp as the program, setting the Expect value to 10, setting all filters to OFF, using BLOSUM62 as the matrix, and setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values) respectively, and performing a search for the identity of a pair of amino acid sequences to calculate the identity value (%), the identity value can then be obtained; the identity of 98% or more can be at least 98%, 99%, or 100% identity.
[0017] The present invention also provides a pseudorabies virus vaccine comprising the recombinant pseudorabies virus or the preparation thereof.
[0018] This invention also provides the application of the recombinant pseudorabies virus or the preparation thereof, for any of the following applications:
[0019] (1) Preparation of pseudorabies virus vaccine;
[0020] (2) Prepare immunosuppressive products that regulate pseudorabies virus.
[0021] The present invention discloses the following technical effects:
[0022] This invention utilizes CRISPR / Cas9 gene editing technology to construct a pseudorabies mutant attenuated strain with a specific deletion mutation in the US2 gene. After infection of host cells, the resulting pseudorabies mutant attenuated strain induced significantly increased expression of type I IFNb and downstream ISG genes, while viral replication itself showed no significant difference. Therefore, the US2 gene deletion mutation can significantly reduce immunosuppression caused by pseudorabies virus and has important potential application value.
[0023] This invention is the first to discover that the mesenteric protein US2 is a key protein in pseudorabies variants that induce host immunosuppression. It significantly inhibits the expression of host type I IFNb and downstream ISGs, thereby suppressing host innate immunity and promoting viral immune escape. Therefore, constructing a pseudorabies variant with a US2 gene deletion is an effective method for developing novel pseudorabies virus gene-deleted vaccines. Attached Figure Description
[0024] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0025] Figure 1 The figures show the PCR identification results of colonies after transformation of pX459-gRNA1 and pX459-gRNA2 in Example 1; M in the figure is the DNA molecular weight standard (DL2000 DNA marker), 1 is a single colony sample of pX459-gRNA1, 2 is a single colony sample of pX459-gRNA2, and NC is the negative control (deionized water).
[0026] Figure 2 The results of PCR identification of plaques of the US2 gene deletion mutant monoclonal virus in Example 1 are shown in the figure. M is the DNA molecular weight standard (DL2000 DNA marker), 1 is the DNA of plaque monoclonal virus No. 1, PC is the positive control (wild-type pseudorabies virus HeNZZ strain DNA), and NC is the negative control (deionized water).
[0027] Figure 3 The image shows the DNA sequence of the US2 gene deletion mutant monoclonal virus in Example 1; PRV-WT in the figure is the wild-type pseudorabies virus HeNZZ strain, and PRV-△US2 is the US2 gene deletion mutant pseudorabies virus HeNZZ strain.
[0028] Figure 4 The figure shows the amino acid sequence sequencing results of the US2 gene deletion mutant monoclonal virus in Example 1; PRV-WT is the wild-type pseudorabies virus HeNZZ strain, and PRV-△US2 is the US2 gene deletion mutant pseudorabies virus HeNZZ strain.
[0029] Figure 5 The results show the effect of US2 gene deletion on IFNb expression in Example 2; PRV-WT in the figure represents wild-type pseudorabies virus HeNZZ strain, and PRV-△US2 represents US2 gene-deleted pseudorabies virus HeNZZ strain; the data shown are expressed as mean ± standard deviation (Mean ± SD), * indicates P≤0.05, ** indicates P≤0.01 (Student's t test);
[0030] Figure 6 The results of the effect of US2 gene deletion on pseudorabies virus replication in Example 2 are shown; PRV-WT in the figure is the wild-type pseudorabies virus HeNZZ strain, and PRV-△US2 is the US2 gene deletion mutant pseudorabies virus HeNZZ strain.
[0031] Figure 7 The results show the effects of US2 on IFNb and downstream ISG15 expression in the mechanism verification experiment; Vec is the empty vector control group, and US2 is the US2 overexpression experimental group; A: IFNb; B: ISG15; the data shown are expressed as mean ± standard deviation (Mean ± SD), * indicates P≤0.05 (Student's t test). Detailed Implementation
[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0033] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included within the scope of this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0034] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.
[0035] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be readily apparent to those skilled in the art. This specification and embodiments are merely exemplary.
[0036] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.
[0037] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the materials and reagents used in the following examples are conventional biochemical reagents and are commercially available.
[0038] 1. Molecular Biology Reagents
[0039] Bbs I enzyme (NEB#R3539) is a NEB product.
[0040] Lipofectamine 2000 (11668019) is a product of ThermoFisher.
[0041] 2. Vectors, cell lines, and virus strains
[0042] pX459 vector (Addgene#62988) is an Addgene vector library product.
[0043] JM109 Escherichia coli (9052) is a product of Dalian Takara Bio Co., Ltd.
[0044] Porcine alveolar macrophage cell line (3D4 / 21) CRL-2843), HEK-293T cells ( ACS-4500), BHK-21 cells ( CCL-10), PK-15 All CCL-33 products are ATCC products.
[0045] The pseudorabies virus HeNZZ strain (GenBank: OQ744679.1) was provided by the International Joint Center for Animal Immunology, Henan Agricultural University.
[0046] 3. Solution and culture medium
[0047] The solutions and culture media used in the following examples were prepared as follows:
[0048] The preparation method of LB medium containing ampicillin resistance is as follows (taking 200mL as an example): Solid LB medium (200mL): 1g yeast extract, 2g trypsin, 2g sodium chloride, 3g agar powder, dissolved in 200mL deionized water, autoclaved at 120℃ for 20min, when the medium temperature drops to 50℃, add 200μL ampicillin antibiotic (100mg / mL) in a clean bench, mix well and pour into a petri dish, store at 4℃ after solidification.
[0049] The preparation method of DMEM medium containing 10% fetal bovine serum (FBS) is as follows (taking 500 mL as an example): add 50 mL of FBS and 5 mL of penicillin-streptomycin antibiotics (5000 U / mL) to 450 mL of DMEM medium and mix thoroughly.
[0050] Opti-MEM medium (31985088) and FBS (A3160901) are Gibco products, as are penicillin-streptomycin (5000 U / mL) (15070063) and DMEM medium (11995065).
[0051] Example 1: Construction of a pseudorabies virus strain with the US2 gene deletion (i.e., a recombinant pseudorabies virus with the US2 gene deletion mutation).
[0052] This embodiment uses CRISPR / Cas9 gene editing technology to specifically delete the US2 gene of the HeNZZ strain of pseudorabies virus. The specific operation is as follows:
[0053] 1. Construction and identification of the US2 gene knockout vector
[0054] 1.1 The amino acid sequence of the US2 protein of pseudorabies virus HeNZZ strain is shown in SEQ ID No.1 in the sequence listing.
[0055] The amino acid sequence of the US2 protein (SEQ ID No. 1):
[0056] MGVTAITVVTLMDGAGRIPAFVGEAHPDLWKVLTEWCYASMVQQRRAADENSPRQHVVLRSSEISPGSLALLPRAVRPVVRRTRSDPTAPFYITTETHELTRRPPADGSKPGEPLRISPPPRLDTEWSS VLNGIQYLNSGARGTAPVHLWILGAADLCDQVLLAASRSTAAGASHAQTGARLTRRRPGLTDADALDVIVAGIQATRAMFARVHNRSWRHAGEWTEALHSQIVTRGDVRRRRGGRGNGRERAPRCTIS.
[0057] The gene sequence of the US2 gene of the pseudorabies virus HeNZZ strain was referenced from the gene sequence of HeNZZ (Suid herpesvirus1 isolate HeNZZ / 2017) in GenBank (GenBank: OQ744679.1).
[0058] To knock out the pseudorabies virus US2 gene, two segments in the US2 gene sequence that conform to the 5'-N sequence were selected. 20 -NGG-3' or 5'-CCN-N 20 The segment with the -3' sequence arrangement rule is the target sequence, where N represents any one of A, G, C, and T. 20This represents 20 consecutive deoxyribonucleotides. The two target sequences are denoted as target sequence 1 and target sequence 2. Based on the website http: / / crispr.mit.edu / , design gRNA sequences targeting possible target sequences 1 and 2.
[0059] In this embodiment, the sequence of target sequence 1 is 5'-CAGGATCCACAGGTGGATCGGGG-3' (SEQ ID No. 2), and the gRNA targeting target sequence 1 is named gRNA1, with the sequence of gRNA1 being 5'-CAGGATCCACAGGTGGATCG-3' (SEQ ID No. 4). The sequence of target sequence 2 is 5'-CAGGGCCTCCGTCCACTCGCCGG-3' (SEQ ID No. 3), and the gRNA targeting target sequence 2 is named gRNA2, with the sequence of gRNA2 being 5'-CAGGGCCTCCGTCCACTCGC-3' (SEQ ID No. 5).
[0060] 1.2 Primer phosphorylation and annealing
[0061] DNA primers F and R (specifically F1 and R1 for gRNA1, and F2 and R2 for gRNA2) were designed and synthesized for the gRNA gene of the US2 gene.
[0062] F1: (SEQ ID No. 6) (The underlined sequence is the Bbs I sticky terminal sequence, and the double underlined sequence is the sequence that is inversely complementary to R1);
[0063] R1: (SEQ ID No. 7) (The underlined sequence is the Bbs I sticky terminal sequence, and the double underlined sequence is the sequence that is inversely complementary to F1).
[0064] F2: (SEQ ID No. 8) (The underlined sequence is the Bbs I sticky terminal sequence, and the double underlined sequence is the sequence that is inversely complementary to R2);
[0065] R2: (SEQ ID No. 9) (The underlined sequence is the Bbs I sticky terminal sequence, and the double underlined sequence is the sequence that is inversely complementary to F2).
[0066] The synthesized F and R primers were annealed to obtain double-stranded complementary sequences. The primer annealing reaction system consisted of: 1 μL of forward primer F (100 μM), 1 μL of reverse primer R (100 μM), 1 μL of 10×T4 ligase buffer, 1 μL of T4 DNA ligase, and 6 μL of H2O, for a total volume of 10 μL. The reaction was performed in a PCR instrument at 37℃ for 30 min, 95℃ for 5 min, and a PCR gradient cooling to 25℃ at a rate of 0.1℃ per second to obtain the annealed primers. These were then stored on ice or at -20℃ for later use. The resulting double-stranded complementary DNA (hereinafter referred to as F1-R1) was obtained from the annealing of F1 and R1; the resulting double-stranded complementary DNA (hereinafter referred to as F2-R2) was obtained from the annealing of F2 and R2.
[0067] 1.3 Construction of Recombinant Vectors
[0068] 1) Construction and identification of pX459-gRNA
[0069] The purified pX459 vector was digested with BBSI enzyme. The reaction mixture consisted of 6-10 μg of pX459 vector, 2 μL of BBSI enzyme, 5 μL of 10× buffer, and H2O to a final volume of 50 μL. After incubation at 37°C for 2 h, the product was subjected to agarose gel electrophoresis, and the pX459 vector backbone was purified by gel excision. Then, F1-R1 molecules were ligated to the purified pX459 vector backbone using the following mixture: 2 μL of F1-R1, 100 ng of pX459 vector backbone, 1 μL of 10×T4 ligase buffer, 1 μL of T4 DNA ligase, and ultrapure water to a final volume of 10 μL. The mixture was incubated overnight at 16°C in a metal ligator. After ligation, the cells were transformed into JM109 competent E. coli cells and screened for positive bacteria on ampicillin-resistant plates. After incubation at 37℃ for 12 h, single colonies were picked using a sterile pipette tip and cultured overnight at 37℃ and 220 rpm in LB medium containing ampicillin. The recombinant vector was extracted for PCR identification. The recombinant vector was identified using the forward primer F1 of gRNA1 and CAG-R (5'-GTACTGGGCACAATGCCAG-3' (SEQ ID No. 10)) as the upstream and downstream primers. The PCR product size was 490 bp. Reaction system and PCR conditions: 1 μL template DNA, 0.5 μL each of upstream and downstream primers, 2.5 μL 10× buffer, 2 μL 2.5 mM dNTPs, 0.125 μL rTaq, and ultrapure water to a total volume of 25 μL. Reaction conditions: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 57℃ annealing for 30 s, 72℃ extension for 1 min, for a total of 30 cycles; final extension at 72℃ for 10 min. PCR products were analyzed by 1% agarose gel electrophoresis, and the identification results are shown below. Figure 1Positive clones should be confirmed by sequencing. Clones with pX459 inserted gRNA1 are sequenced using CAG-R primers; recombinant vectors with correct sequencing are named pX459-gRNA1. Clones with pX459 inserted gRNA2 are sequenced using CAG-R primers; recombinant vectors with correct sequencing are named pX459-gRNA2. pX459-gRNA1 and pX459-gRNA2 are gRNA gene expression vectors obtained by inserting gRNA1 and gRNA2 sequences, respectively, into the Bbs I recognition site of pX459, while keeping other nucleotides of pX459 unchanged.
[0070] 2. Construction of US2 gene deletion mutant pseudorabies virus
[0071] HEK-293T cells were co-transfected with recombinant vectors pX459-gRNA1 and pX459-gRNA2. The transfection system is shown in Table 1.
[0072] Table 1. Reaction system for Lip2000 transfection of HEK-293T cells (12-well plate)
[0073] Serial Number Reagents (per well) Added amount A1 Opti-MEM medium 100μL A2 Lipofectamine 2000 2μL B1 Opti-MEM medium 100μL B2 pX459-gRNA1 0.5μg B3 pX459-gRNA2 0.5μg
[0074] Procedure: First, mix reagents A1 and A2 from Table 1 thoroughly to obtain liquid group A. Then, mix reagents B1 and B2 thoroughly to obtain liquid group B. Next, mix liquid group A and liquid group B together thoroughly and let stand at room temperature for 20 minutes. Add the reaction product evenly to HEK-293T cells cultured in DMEM medium containing 10% FBS. Incubate at 37°C and 5% CO2 for 24 hours. Infect the cells with the pseudorabies virus strain HeNZZ at an MOI of 1. Collect the virus solution after 24 hours and store at -80°C.
[0075] 3. Screening for pseudorabies virus with US2 gene deletion mutation
[0076] The collected viral fluid was purified by plaque phage in BHK-21 cells, and monoclonal viruses were picked.
[0077] The specific procedure is as follows: Seed BHK-21 cells onto a six-well plate; the cells must aggregate into a monolayer before experiments can be performed. Serially dilute the collected virus solution with pure DMEM (usually using 10⁻⁶ DMEM). -2 Up to 10 -5(Dilution). Discard the original nutrient solution in the cell plate, wash the cell surface 2-3 times with pure DMEM, and add diluted virus (100 μL / well). After mixing by tilting the cell plate at different angles, incubate at 37°C for 1 hour. During this period, remove the cell plate every 15 minutes and tilt it to mix to ensure uniform virus distribution. After incubation, discard the virus solution, mix 5% 2×DMEM and melted low-melting-point agar 1:1, and add it to the cell plate wells. Place the cell plate in a 4°C freezer for 5 minutes to allow the agar to completely solidify. After solidification, place the cell plate in a 37°C incubator and invert it for several days (usually 4-5 days). Add crystal violet staining solution to the cell plate to cover the cell wells, place the cell plate in a 37°C incubator for 2-3 hours, and rinse the agar out of the cell plate wells with water. Clearly visible plaques will be visible. Pick one plaque, extract viral DNA to obtain plaque monoclonal virus DNA 1, and perform PCR identification.
[0078] Using extracted plaque monoclonal virus DNA as a template, wild-type pseudorabies virus HeNZZ strain DNA as a positive control, and deionized water as a negative control, PCR amplification was performed using the full-length US2 primers (primer sequences US2 F: 5'-ATGGGGGTGACGGCCATCACCGTGG-3' (SEQ ID No. 11); US2 R: 5'-CTAGGAGATGGTACATCGCGGGGCG-3' (SEQ ID No. 12)). The following mixture was used: 2 μL template DNA; 1 μL each of forward and reverse primers; 25 μL 2×GC buffer; 4 μL 2.5 mM dNTPs; 0.25 μL rTaq; and ultrapure water to a total volume of 50 μL. Reaction conditions: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 60℃ annealing for 30 s, 72℃ extension for 1 min, for a total of 30 cycles; final extension at 72℃ for 10 min. The products were analyzed by 1% agarose gel electrophoresis. The PCR fragment length was 545 bp. The fragments were excised and recovered from the gel. The recovered products were then sequenced to determine the knockout effect of the US2 gene. Electrophoresis results are shown below. Figure 2 The sequencing results and amino acid sequence results of the US2 gene of the deletion mutant virus are shown in [link to gene sequencing results]. Figure 3 and Figure 4 The results showed that the US2 gene of the gene-deleted virus was missing 226 bp compared with the normal virus, resulting in a change in the amino acid sequence it encodes. This indicated that the monoclonal pseudorabies variant strain HeNZZ with the US2 gene deletion mutation was successfully obtained, and the strain was named recombinant pseudorabies virus with the US2 gene deletion mutation.
[0079] Example 2: Effects of US2 gene deletion on host innate immune response and pseudorabies virus replication
[0080] 1. The effect of US2 gene deletion on IFNb
[0081] Porcine alveolar macrophage cell line (3D4 / 21) was 2.5 × 10⁻⁶ cells / year. 5 Cells were seeded per well in 12-cell plates and cultured overnight at 37°C with 5% CO2. Recombinant pseudorabies virus with US2 gene knockout and the wild-type pseudorabies virus HeNZZ strain were used to infect 3D4 / 21 cells at MOI=1. RNA samples were collected at 0h, 12h, and 24h post-infection and reverse transcribed into cDNA. The constitutively expressed GAPDH gene was used as an internal control to homogenize the cDNA concentration. Quantitative real-time PCR was used to detect the expression of type I IFNb gene. The upstream and downstream primer sequences for PCR detection of type I IFNb gene were as follows:
[0082] pIFNb-F: 5'-TGCATCCTCCAAATCGCTCT-3' (SEQ ID No. 13);
[0083] pIFNb-R: 5'-ATTGAGGAGTCCCAGGCAAC-3' (SEQ ID No. 14).
[0084] The upstream and downstream primer sequences for the internal reference GAPDH gene are as follows:
[0085] pGAPDH-F:5'-TACACTGAGGACCAGGTTGTG-3' (SEQ ID No. 15);
[0086] pGAPDH-R: 5'-TTGACGAAGTGGTCGTTGAG-3' (SEQ ID No. 16).
[0087] The quantitative PCR reaction system consisted of 5 μL of 2×SYBR Premix Ex Taq, 0.2 μL each of forward and reverse primers, 2 μL of template, and ultrapure water to a final volume of 10 μL. The quantitative PCR reaction conditions were: 95℃ for 2 min; 95℃ for 15 s, 60℃ for 20 s, 72℃ for 30 s, for 40 cycles. Results are shown below. Figure 5 The expression level of type I IFNb gene was 1 at 0h after infection with wild-type pseudorabies virus HeNZZ strain (marked as PRV-WT in the figure). Compared with wild-type pseudorabies virus HeNZZ strain (marked as PRV-WT in the figure), recombinant pseudorabies virus with US2 gene deletion mutation (marked as PRV-△US2 in the figure) could significantly induce the expression of type I IFNb gene.
[0088] 2. The effect of US2 gene deletion mutation on pseudorabies virus replication
[0089] Using extracted pseudorabies virus DNA as a template, PCR amplification was performed using gD gene primers (gD F: 5'-CACGGAGGACGAGCTGGGGCT-3' (SEQ ID No. 17); gD R: 5'-GTCCACGCCCCGCCTGAAGCT-3' (SEQ ID No. 18)): 2 μL template DNA; 1 μL each of forward and reverse primers; 25 μL 2×PrimeSTAR GC buffer; 4 μL 2.5 mM dNTP; 0.25 μL PrimeSTAR; and ultrapure water to a total volume of 50 μL. Reaction conditions: 98℃ pre-denaturation for 3 min; 98℃ denaturation for 10 s, 58℃ annealing for 30 s, 72℃ extension for 30 s, for a total of 30 cycles; final extension at 72℃ for 10 min. The product was analyzed by 1% agarose gel electrophoresis. The PCR fragment length was 217 bp. The fragment was excised and recovered from the gel. The DNA concentration of the product was determined. The nucleic acid copy number was calculated using the formula for DNA concentration and nucleic acid copy number. dsDNA: (6.02 × 10⁻⁶) 23 (Copies / molar) × (Concentration g / ml) / (MW g / mol) = copies / ml. The recovered product was used as a standard and serially diluted. The diluted standard was then used as a template for quantitative real-time PCR amplification of the gD gene using upstream and downstream primers. The system automatically generated a standard curve: y = -3.824x + 49.102, R0. 2 =0.999, where y is the CT value and x is the exponent of the copy number log10.
[0090] porcine kidney cells (PK-15) were cultured at 1.5 × 10⁻⁶. 5 Cells were seeded per well in 12-cell plates and cultured overnight at 37°C with 5% CO2. Recombinant pseudorabies virus with the US2 gene deletion mutation (Example 1) and wild-type pseudorabies virus HeNZZ strain were infected with PK-15 cells at an MOI of 0.1. Cell samples were collected at 0h, 12h, 24h, 36h, and 48h post-infection. Total DNA was extracted from the samples, and pseudorabies virus replication was detected by quantitative real-time PCR. The CT values of pseudorabies virus detected by quantitative real-time PCR were substituted into a standard curve to calculate the viral copy number. Results are shown below. Figure 6 Compared with the wild-type pseudorabies virus HeNZZ strain (marked as PRV-WT in the figure), the deletion of the US2 gene had no significant effect on viral replication (marked as PRV-△US2 in the figure).
[0091] 3. Mechanism verification experiment
[0092] To verify the effect of US2 on IFNb expression, porcine kidney cells (PK-15) expressing US2 and control cells expressing the empty vector were cultured at a concentration of 1.5 × 10⁻⁶ cells / year. 5Cells were seeded per well in 12-cell plates and incubated overnight at 37°C with 5% CO2. B-DNA (1 μg / mL) was transfected into both groups of cells. RNA samples were collected at 0 h, 6 h, and 12 h post-transfection and reverse transcribed into cDNA. The cDNA concentration of the samples was homogenized using the GAPDH gene as an internal control. The expression of type I IFNb (primer sequences: pIFNb-F: 5'-TGCATCCTCCAAATCGCTCT-3' (SEQ ID No. 13); pIFNb-R: 5'-ATTGAGGAGTCCCAGGCAAC-3' (SEQ ID No. 14)) and the downstream ISG15 gene (primer sequences: pISG15-F: 5'-GCACAGCAATCATGAGTGAGAC-3' (SEQ ID No. 19); pISG15-R: 5'-CTGGCCCCTGCAGTCTTTTA-3' (SEQ ID No. 20)) was detected by real-time PCR. The real-time PCR reaction system consisted of 5 μL of 2×SYBRPremix Ex Taq, 0.2 μL each of the forward and reverse primers, 2 μL of template, and ultrapure water to a final volume of 10 μL. The quantitative PCR reaction conditions were: 95℃ for 2 min; 95℃ for 15 s, 60℃ for 20 s, 72℃ for 30 s, for 40 cycles. Results are shown below. Figure 7 With the expression level of type I IFNb gene in control cells transfected for 0 h as 1, compared with cells overexpressing US2, the US2 gene could significantly inhibit B-DNA-induced expression of host IFNb and downstream ISG15.
[0093] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims
1. A method for constructing a recombinant pseudorabies virus, characterized in that, The recombinant pseudorabies virus was obtained by deleting the US2 gene from pseudorabies virus; The construction method includes the following steps: inhibiting the expression of the US2 gene in pseudorabies virus to obtain recombinant virus; The inhibition of US2 gene expression in pseudorabies virus was achieved through CRISPR / Cas9 gene editing. In the CRISPR / Cas9 gene editing method, the nucleotide sequence of the target sequence of the gRNA targeting the US2 gene is shown in SEQ ID No. 2 and SEQ ID No. 3; the sequence of the gRNA is shown in SEQ ID No. 4 and SEQ ID No.
5.
2. The construction method according to claim 1, characterized in that, The steps for inhibiting the expression of the US2 gene in pseudorabies virus are as follows: a gRNA for specifically targeting the target gene is designed according to the target sequences shown in SEQ ID No. 2 and SEQ ID No.
3. The gRNA is then ligated to a linearized vector, transformed, extracted, and transfected, and then used to infect wild-type strains to obtain the recombinant pseudorabies virus.
3. The application of the recombinant pseudorabies virus constructed by the method described in claim 1 or 2 in any of the following: (1) Preparation of pseudorabies virus vaccine; (2) Prepare immunosuppressive products that regulate pseudorabies virus.
